This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Diagnoses for sexually transmitted infections, or STIs, are increasing in older adults. The Centers for Disease Control and Prevention reports the number of people older than 65 diagnosed with chlamydia, gonorrhea or syphilis in the U.S. increased about three-, five- and sevenfold, respectively, from 2010 to 2023.
Longeveron and Lexeo Therapeutics are working on CGT therapies to treat Alzheimer’s disease, but it’s not clear whether they have a better chance of success than traditional approaches.
The Union health ministry has initiated the process to fill in the top most post in the Central Drugs Standard Control Organisation (CDSCO), with the tenure of the current Drugs Controller General of India (DCGI) expected to come to an end by February next year.
An FDA advisory committee has recommended approval of Zevra Therapeutics' arimoclomol for the ultra-rare disorder Niemann-Pick disease, three years after the regulator rejected the drug.The Genetic Metabolic Diseases Advisory Committee (GeMDAC) voted 11 to five that the data support the approval of the drug for Niemann-Pick disease type C (NPC), a progressive genetic disorder that leads to the accumulation of fatty substances in tissues and can cause a range of symptoms, including liver and lung
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
This Teachable Moment describes a 62-year-old man with thyrotoxicosis due to excess levothyroxine exposure during tirzepatide treatment that induced rapid weight loss.
13th Conference of the International Leptospirosis Society (ILS) and 4th Meeting of the European Leptospirosis and other rodent-borne haemorrhagic fevers Society (ELS) Event type: symposium Audience: scientists Description: You are kindly invited to the 13th Conference of the International Leptospirosis Society ( ILS ) and 4th Meeting of the European Leptospirosis and other rodent-borne haemorrhagic fevers Society ( ELS ).
Prescribing rates of glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonists are increasing rapidly, given their recently demonstrated efficacy in causing weight loss. Additional benefits include reduction in cardiovascular risk in patients with obesity, diabetes, and chronic kidney disease; decreased heart failure–related symptoms in patients with a preserved ejection fraction; and improved glycemic control.
Prescribing rates of glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonists are increasing rapidly, given their recently demonstrated efficacy in causing weight loss. Additional benefits include reduction in cardiovascular risk in patients with obesity, diabetes, and chronic kidney disease; decreased heart failure–related symptoms in patients with a preserved ejection fraction; and improved glycemic control.
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim a
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content